More Articles

Indian Ranbaxy buys Biovel to strengthen in vaccines and follow-on biologics Pharma News | Posted 12/02/2010

Ranbaxy Laboratories in India (now part of Daiichi Sankyo) has strengthened its vaccine and biologicals manufacturing capabilities by acquiring India-based Biovel Lifesciences.

Japan wants to stimulate generics and biosimilars Policies & Legislation | Posted 12/02/2010

As reported by Ian Haydock in Scrip News of 19 January 2010, the debate over reforms to Japan's drug reimbursement pricing system is continuing to inch ahead, with signs emerging that the changes c...

Indian firms seek a higher profile in biosimilars Generics/Research | Posted 12/02/2010

As reported by Anju Ghangurde in Scrip News of 13 January 2010, large Indian companies appear to be keen to develop their capacities and capabilities in the biosimilars segment, an area expected to...

Physicians still have concerns about the quality, reliability and interchangeability of certain generic medicines Generics/Research | Posted 11/02/2010

In a study by Dr Mohamed Azmi Hassali et al. of the Universiti Sains Malaysia (USM), as published in the January 2010 Journal of Generic Medicines issue (published online 1 September 2009), physici...

Opportunities and challenges to implementing the Quality by Design approach in generic drug development Generics/Research | Posted 11/02/2010

In an article by Dr Ramaji Varu of Biocon, Bangalore, India, and Dr Amit Khanna of Novartis, Hyderabad, India, published in the January 2010 Journal of Generic Medicines issue (published online 17...

Pharmalot: Are pay-for-delay deals good or bad? Pharma News | Posted 11/02/2010

On 13 January 2010, the Federal Trade Commissioner (FTC) Jon Leibowitz held a press conference to deride the ongoing practice in which brand-name drugmakers offer cash or some other inducement to t...

FTC Chairman and US Congress members call for US legislation to end ‘pay-for-delay’ deals Policies & Legislation | Posted 10/02/2010

On 13 January 2010, US Federal Trade Commission (FTC) Chairman Jon Leibowitz and key members of US Congress, including Representative Chris Van Hollen, Chairman Bobby Rush, and Representative Mary...

PhRMA threatens to withdraw US healthcare reform support Pharma News | Posted 10/02/2010

As reported by PharmaTimes on 18 January 2010, US research-based drugmakers have threatened to withdraw their support for US President Barack Obama’s healthcare reforms unless biological drugs rece...